Stock Analysis on Net
Stock Analysis on Net

Bristol-Myers Squibb Co. (NYSE:BMY)

$19.99

Cash Flow Statement

The cash flow statement provides information about a company cash receipts and cash payments during an accounting period, showing how these cash flows link the ending cash balance to the beginning balance shown on the company balance sheet.

The cash flow statement consists of three parts: cash flows provided by (used in) operating activities, cash flows provided by (used in) investing activities, and cash flows provided by (used in) financing activities.

Paying users area

Try for free

Bristol-Myers Squibb Co. pages available for free this week:

The data is hidden behind: . Unhide it.

  • Get 1-month access to Bristol-Myers Squibb Co. for $19.99, or

  • get full access to the entire website for at least 3 months from $49.99.

Get access

This is a one-time payment. There is no automatic renewal.

We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Bristol-Myers Squibb Co., consolidated cash flow statement

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017
Net earnings (loss)
Depreciation and amortization, net
Deferred income taxes
Stock-based compensation
Impairment charges
Pension settlements and amortization
Divestiture gains and royalties
IPRD charge, MyoKardia acquisition
Asset acquisition charges
Equity investment (gains) losses, net
Contingent consideration fair value adjustments
Other adjustments
Receivables
Inventories
Accounts payable
Rebates and discounts
Income taxes payable
Other
Changes in operating assets and liabilities
Adjustments to reconcile net earnings (loss) to net cash provided by operating activities
Net cash provided by operating activities
Sale and maturities of marketable debt securities
Purchase of marketable debt securities
Proceeds from sales of equity investment securities
Capital expenditures
Divestiture and other proceeds
Acquisition and other payments, net of cash acquired
Net cash used in investing activities
Short-term debt obligations, net
Issuance of long-term debt
Repayment of long-term debt
Repurchase of common stock
Dividends
Other
Net cash provided by (used in) financing activities
Effect of exchange rates on cash, cash equivalents and restricted cash
Increase (decrease) in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash at beginning of year
Cash, cash equivalents and restricted cash at end of year

Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).

Cash flow statement item Description The company
Net cash provided by operating activities Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. Bristol-Myers Squibb Co. net cash provided by operating activities increased from 2019 to 2020 and from 2020 to 2021.
Net cash used in investing activities Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. Bristol-Myers Squibb Co. net cash used in investing activities decreased from 2019 to 2020 but then increased from 2020 to 2021 exceeding 2019 level.
Net cash provided by (used in) financing activities Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. Bristol-Myers Squibb Co. net cash provided by (used in) financing activities decreased from 2019 to 2020 and from 2020 to 2021.